January Therapeutics Adds Harvard’s Miles Miller to Scientific Advisory Board

SAN DIEGO – April 6, 2022 – January Therapeutics, a leading biotechnology company developing targeted medicines for cancer, announced today the addition of Miles Miller, PhD to the company’s scientific advisory board. Miller is faculty at Harvard Medical School, and is an expert in nanoparticle and albumin-based drug delivery systems. He joins January Therapeutic’s larger advisory board of distinguished scientists and physicians to help guide development of the company’s albumin-based nanoparticle drug delivery platform.

Miller’s laboratory studies use of nanomaterials for localized therapy, cellular reprogramming in cancer, and multi-scale dissection of the tumor microenvironment. In 2021, his lab published groundbreaking research identifying that KRAS mutant cancer cells undergo reprogramming of nutrient signaling that enhances albumin nanoparticle drug uptake and efficacy. This discovery provides rationale for the biomarker-based patient selection approach of January’s albumin nanoparticle therapies.

“The team at January is developing advanced albumin-based nanoparticle therapeutic products that have the potential to deliver optimized pharmacokinetics, efficacy and safety,” said Miller. “It is exciting to join the effort and help translate scientific discoveries into new therapies that can make a direct impact on patient care.”

“We are thrilled to add a scientist and domain expert of Miles’ caliber to our scientific advisory board,” said Thomas Broudy, CEO of January Therapeutics. “Miles is a leading expert in drug delivery and the biology of altered cancer cell metabolism, including albumin uptake. Our platform and the therapies we are developing will benefit greatly from the insight and guidance he brings to our advisory board.”

Miller is an Assistant Professor in the Department of Radiology at Harvard Medical School and Principal Investigator in the Center for Systems Biology at Massachusetts General Hospital. He serves as a member of the Developmental Therapeutics program at the Dana Farber / Harvard Cancer Center, and is a faculty of the Harvard Medical School Bioinformatics and Integrative Genomics PhD Program. He is an awardee of the NIH New Innovator and NCI Pathway to Independence Award. Miller performed his postdoctoral fellowship at Massachusetts General Hospital. He earned his PhD in Biological Engineering from Massachusetts Institute of Technology.

About January Therapeutics
January Therapeutics develops next generation targeted medicines for cancer. Our platform centers around albumin-encapsulation, which enables novel small molecule payloads, tumor-specific nanoparticle delivery and biomarker-based patient selection. This allows us to maximize therapeutic window and deliver efficacy in ways that other drugs have struggled to address. Our pipeline comprises 5 internal programs and multiple external partnerships.

To learn more, visit https://januarytx.com.

Investor relations:
Sam Ellis
sam.ellis@januarytx.com

January Therapeutics Appoints Thomas Broudy CEO

SAN DIEGO – March 7, 2022

January Therapeutics, a leading biotechnology company developing targeted medicines for cancer, announced today the appointment of Thomas B. Broudy, PhD, as Chief Executive Officer. Broudy will lead the company’s strategic direction and hold responsibility for advancing the company’s therapeutic programs to their upcoming milestones—including internal development and external partnerships.

“The Board is excited to have someone with Dr. Broudy’s experience lead January Therapeutics through its next growth phase,” said Sam Ellis, Chairman of January Therapeutics.  “He is a world-class business and science leader with a 20-year history growing biotechnology companies in precision medicine, drug discovery and development.  His experience and passion starting companies, building teams, and creating value makes him the exact kind of leader January needs to achieve our goals of delivering more effective therapies to patients in need.”

“I am thrilled to join January, a company with an exciting oncology therapeutic pipeline, enabling technology and passionate team,” said Thomas Broudy, PhD, CEO. “Drug delivery is a major challenge for many oncology therapeutics, forcing developers to often compromise drug activity to achieve acceptable deliverability.  The enabling technology we have at January breaks this tradeoff, allowing us build extremely active molecules that are optimally delivered through our albumin-based nanoparticle technology.  This combination of chemistry, biology and engineering gives us a unique opportunity to build world-class drugs for some of the most challenging targets in oncology.”

Prior to joining January Therapeutics, Broudy most recently served as Executive Vice President, Corporate Development & Marketing at BioDuro-Sundia, where he led go to market strategy for the 2,500 person global CRO/CDMO.  His team’s efforts created a robust deal pipeline, including multiple major partnerships with pharma and biotech. Broudy previously served as General Manager of Crown Bioscience San Diego, where he led the US preclinical oncology operation up to the company’s IPO.  Prior to that, he cofounded and served as CSO of Molecular Response, a patient-derived tumor modeling company, up to the company’s strategic acquisition. Broudy previously served as Director at AltheaDx, leading the Business Development team to partner gene expression-based companion diagnostics for oncology therapeutics.  He spent six years at Affymetrix, where he managed the company’s pharmacogenomic and toxicogenomic solutions in support of pharmaceutical R&D.

Broudy held postdoctoral appointments at Rockefeller University and Stanford University studying host/microbial genomics. He earned his PhD at Rockefeller in the Laboratory of Bacterial Pathogenesis and Immunology.

About January Therapeutics

January Therapeutics develops next generation targeted medicines for cancer.  Our platform centers around albumin-encapsulation, which enables novel small molecule payloads, tumor-specific nanoparticle delivery and biomarker-based patient selection.  This allows us to maximize therapeutic window and deliver efficacy in ways that other drugs have struggled to address.  Our pipeline comprises 5 internal programs and multiple external partnerships.

To learn more, visit https://januarytx.com.

Investor relations:

Sam Ellis
sam.ellis@januarytx.com

January Therapeutics Strengthens Board of Directors with Appointment of Veteran Biotechnology Executive Christopher LeMasters

SAN DIEGO, March 3, 2021

January Therapeutics today announced the appointment of Christopher LeMasters to the Board of Directors. Mr. LeMasters brings more than 30 years of experience as both an executive and strategic advisor, with particular expertise in business development, finance and operations.

“We are excited to announce the appointment of Mr. LeMasters to the Board of Directors,” said Sam Ellis, Chairman of January Therapeutics. “His extensive strategic and transactional experience will serve January well as the Company advances its innovative nanoparticle platform and pipeline of novel anti-cancer agents. We look forward to Mr. LeMasters’ valuable counsel and expertise.”

Mr. LeMasters was most recently the Chief Operating Officer of Amplyx, where he led the successful sale of the company to Pfizer in April 2021 and has overseen the company’s integration for Pfizer following the acquisition. Previously, he was EVP & Chief Business Officer of Mirati Therapeutics where he was part of the company’s turnaround and exponential growth from 2016 to 2020. Mr. LeMasters has also served as an executive, co-founder and board member at multiple private biotech companies since 2004, including Conforma and Cabrellis where he led successful M&A transactions. He is currently a board member for the Hoosier Cancer Research Network, a clinical research organization, and acts as a strategic advisor for several early-stage oncology biotechs. Mr. LeMasters began his career as a management consultant and worked for six years in corporate business development at Eli Lilly & Company. He holds an MBA with Honors from the University of Chicago and a BS from Indiana University.

About January Therapeutics

January Therapeutics is a biotechnology company focused on discovering novel therapeutics that leverage the proven clinical benefits of protein-based nanoparticle formulation.  Their initial development programs are focused in oncology, specifically related to therapeutics that treat sarcomas, ovarian, lung and other solid tumors. Further information about the company and its drug development programs and capabilities may be found online at https://januarytx.com

Contact:

Sam Ellis, Chairman sam.ellis@januarytx.com

January Therapeutics Announces Expansion of Scientific Advisory Board with Appointment of Dr. Terry Williams

SAN DIEGO (PRWEB) November 05, 2021

January Therapeutics today announced the appointment of Terence Williams, MD, PhD as a Scientific Advisory Board Member. Dr. Williams will provide guidance for key aspects to January’s solid tumor initiatives (Pancreatic, Lung and Colorectal), and help on the Company’s better understanding of the metabolic pathways in cancer. Dr. Williams will help our proprietary programs allowing January to solve undruggable issues.

Dr. Williams is the Professor and Chair, Department of Radiation Oncology at the City of Hope National Medical Center. Dr. Williams received both his PhD & MD from Albert Einstein College of Medicine. He completed post-doctoral and residency training at the University of Michigan. He has authored over 120 publications in the field of Oncology and presents regularly.

“We are very pleased to welcome Dr. Terry Williams to January,” said Ellis. “His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to January.”

January Therapeutics is targeting cell-essential drivers of cancer which cannot be successfully drugged by chemistry alone. January’s technology exploits the dysregulated metabolic pathways in cancer and uses albumin to preferentially deliver drug to tumors while sparing healthy cells.

To learn more, visit https://januarytx.com

January Therapeutics Announces New Head Of Early Research and Development

SAN DIEGO (PRWEB) AUGUST 05, 2021

 January Therapeutics announced the appointment of Patrick Kearney, PhD, as Head of Early Research and Development. Dr. Kearney will lead key aspects of the Scientific Team for January’s oncology programs including furthering of the Targeted Oncology Programs, Platform Expansion, and other undisclosed targets.

Dr. Kearney is a former Senior Director of Medicinal Chemistry at Exelixis, where he led teams whose kinase-focused efforts resulted in multiple clinical candidates for oncology and inflammation applications. Additionally, while there, he led both technology development, production, and corporate partnership initiatives to build the company’s screening library. Subsequently, Dr. Kearney founded of HD Sciences to develop nanoparticle-based reagents for use in medicinal chemistry. Immediately prior to joining January Therapeutics, he was a Principal Investigator in Chemistry at Deciphera Pharmaceuticals, where led a team to identify novel kinase inhibitors with that company’s core technology platform. 

Dr. Kearney received his B.S. from Carnegie Mellon University and a Ph.D. in Chemistry from the California Institute of Technology. He is listed as an inventor on 20 patent applications and as an author on 17 peer-reviewed articles. 


“We are very pleased to welcome Dr. Kearney to January.” said Sam Ellis, CEO of January Therapeutics. “His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to help patients with cancer. His ability to build teams, and bring success will help January Therapeutics grow to the next level.”

January Therapeutics today announced the appointment of Dr. Paul Grint to the Board of Directors

SAN DIEGO (PR WEB) MAY 5, 2021

Dr. Grint has served as the Executive Chairman of the Board of Directors of Cardea Bio since April 2020. He also has served as a member of the Board of Directors and as a member of the compensation committee of Amplyx Pharmaceuticals, Inhibikase Therapeutics and Synedgen.

From 2017 to 2019, Dr. Grint served as Chief Executive Officer of AmpliPhi Biosciences and as a member of AmpliPhi Bioscience’s Board of Directors from 2015 to 2019, additionally from 2014 to 2017 Dr. Grint served as Chief Executive Officer of Regulus Therapeutics, Inc., both publicly traded clinical stage biopharmaceutical companies.

Dr. Grint has more than two decades of experience in biologics and small-molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas. Dr. Grint has also served in senior management roles at Cerexa, Forest Laboratories, Kalypsys, Pfizer, IDEC Pharmaceuticals, and Schering-Plough Corporation. He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and holds a B.Sc. from St. Mary’s Hospital College, University of London and an M.B. and B.S. from St. Bartholomew’s Hospital College, University of London. 

“We are very pleased to welcome Dr. Grint as a member of the Board of Director’s” said Sam Ellis, CEO of January Therapeutics. “Dr. Grint’s leadership experience as both a Chief Executive Officer and as a director of privately held and public companies along with his significant experience in clinical pharmaceutical development makes him an important addition to our Board of Directors.”

January Therapeutics is a biotechnology company focused on discovering novel therapeutics that leverage the proven clinical benefits of protein-based nanoparticle formulation. Their initial development programs are focused in oncology, specifically related to therapeutics that treat sarcomas, ovarian, lung and other solid tumors.

January Therapeutics Announces Appointment of Dr. Daniel C. Maneval, PhD as Chief Scientific Officer

SAN DIEGO (PRWEB) APRIL 27, 2021 

January Therapeutics today announced the appointment of Daniel C. Maneval, PhD, as Chief Scientific Officer. Dr. Maneval will lead key aspects of the Scientific Team for January’s oncology programs including the JNTX-101 program (pro-drug albumin-encapsulated version of gemcitabine for cancer treatment) and JNTX-104 (albumin-encapsulated 8-chloro-adenosine for AML), and other undisclosed targets.

Dr. Maneval is the former Vice President of Research & Nonclinical Development at Halozyme Therapeutics where he led the expansion of Halozyme’s core technology platforms. In that role he was also an integral part of the team working with strategic partners that gained FDA & EMA approval of several products incorporating the Halozyme technology. Prior to Halozyme Dr. Maneval was the Site Head of Schering-Plough’s gene therapy site in San Diego, and he helped lead Herceptin® from a pre-clinical asset through early-phase clinical trials at Genentech.

Dr. Maneval received his B.S. from Boston University in Biomedical Engineering and a Ph.D. in Biomedical Engineering from the University of Southern California. He has authored over 50 publications and is listed as inventor on over 14 patents.

“We are very pleased to welcome Dr. Maneval to January.” said Sam Ellis, CEO of January Therapeutics. “His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to help patients with cancer. His ability to build teams, and bring success will help January Therapeutics grow to the next level.”

January Therapeutics Announces Appointment of Dr. Steven Rosen as Chief Medical Advisor

SAN DIEGO (PRWEB) JANUARY 25, 2021 

January Therapeutics, an oncology-focused biopharmaceutical research and development company, today announced the appointment of Steven Rosen, MD as Chief Medical Advisor. Dr. Rosen will support key aspects of clinical development for January’s JNTX-101 program (Pro-drug albumin-encapsulated version of Gemcitabine – a backbone for many cancer treatments) and JNTX-104 (Pro-drug albumin-encapsulated version of 8-Chloro-Adenosine – a drug that has been used in patients with AML). Dr. Rosen will also lead January’s patient advocacy program.


Dr. Rosen is the Provost and Chief Scientific Officer of the City of Hope National Medical Center. In that role he leads the Beckman Research Institute and the Irell & Manella Graduate School of Biological Sciences. Dr. Rosen received both his BS and MD from Northwestern University where he also completed his residency. He has authored over 450 publications in the field of Oncology and serves on a number of oncology foundation boards including AACR, ASCO, and the Leukemia & Lymphoma Society.


“We are very pleased to welcome Dr. Steve Rosen to January” said Sam Ellis, CEO of January Therapeutics. “His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to January.”

January Therapeutics Announce Research Collaboration with City of Hope

SAN DIEGO (PRWEB) JUNE 17, 2020

January Therapeutics, Inc., a biopharmaceutical research and development company, today announced a research collaboration with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.

The collaboration centers around the application of January’s proprietary Chemistry-enabled Albumin Nanoparticle (CAN) platform to an existing City of Hope drug candidate (a nucleoside- based therapy) that is currently under investigation by City of Hope at the cancer center’s main campus near Los Angeles, California.

“January Therapeutics is thrilled to work alongside City of Hope to apply our novel albumin nanoparticles to their investigational therapy,” said Sam Ellis, CEO of January Therapeutics. Scientists from January will encapsulate the drug candidate in the company’s albumin nanoformulation. Subsequent studies of this new chemical entity will then be conducted by the research teams at City of Hope.

“City of Hope is excited to evaluate the impact that January’s platform can have on our investigational therapy,” said Steven T. Rosen, M.D., provost and chief scientific officer at City of Hope, noting that the concept of albumin encapsulation has been scientifically validated as a means of targeting cancer cells. 

The details of the collaboration were not released, but the company indicated that the collaboration may potentially expand as data from the research becomes available.

January Therapeutics Names Scientific Advisory Board

January Therapeutics, an emerging oncology research and development company, announces a panel of renown scientific advisors

January Therapeutics, Inc., was formed around a proprietary therapeutic platform dubbed the Chemistry-enabled Albumin Nanoparticle (CAN) Platform. The company recently named a number of experts to provide advice on the development of the various compounds in the January pipeline.

“We have assembled a distinctive group of respected leaders in the fields of cancer research and drug development,” said Sam Ellis, January’s CEO, “and we look forward to collaborating with them in the development of our promising pipeline of therapeutics.” 

The scientific advisors include:

  • Gary Schwartz, MD – Division Chief, Hematology/ Oncology and Deputy Director Columbia University Irving Cancer Center
  • David Carbone, MD, PhD – Director, James Thoracic Center at Ohio State University
  • John Nuss, PhD – Inventor of Cabozantinib, Cobimetinib, and Esazerenone. Previously UC Riverside, Chiron, Exelixis
  • Bruce Roth, PhD – Inventor of Lipitor.  Previously Parke-Davis, Warner-Lambert, Pfizer, Genentech